On Thursday, Edwards Lifesciences received a positive adjustment to its Relative Strength (RS) Rating, from 68 to 71.
When To Sell Stocks To Lock In Profits And Minimize Losses
This unique rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the best stocks typically have an RS Rating of above 80 in the early stages of their moves. See if Edwards Lifesciences can continue to rebound and clear that threshold.
Edwards Lifesciences is in a buy range after clearing a 76.73 buy point in a flat base. Once a stock moves 5% or higher beyond the initial entry, it's considered out of a proper buy zone.
Earnings growth picked up last quarter from 7% to 16%. But sales fell from 9% to 6%.
Edwards Lifesciences holds the No. 13 rank among its peers in the Medical-Products industry group. Boston Scientific, Insulet and LifeMD are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
